TCT 2022 | CLASP II D TRIAL: Transcatheter Edge-to-Edge Repair for Mitral Regurgitation in Patients at Prohibitive Risk

The CLASP IID study was a prospective randomized study to assess the efficacy and effectiveness of the PASCAL transcatheter valve repair system compared with the MitraClip device for patients with degenerative mitral regurgitation (MR) at prohibitive surgical risk. The study included Patients at prohibitive surgical risk, candidates for both devices, with MR 3+ to 4+,<a href="https://solaci.org/en/2022/09/21/tct-2022-clasp-ii-d-trial-transcatheter-edge-to-edge-repair-for-mitral-regurgitation-in-patients-at-prohibitive-risk/" title="Read more" >...</a>

TCT 2022 | FRANCE-TAVI Registry: Small Annuli

The presence of small annuli, defined in this registry as < 23 mm diameter or indexed diameter <12 mm/m2 by CT, continues to be one of the greatest challenges of both surgical and endovascular aortic valve treatments. The FRANCE-TAVI Registry looked at 1,195 patients presenting small annuli. 895 (74.9%) received balloon expandable valves (BEV) and<a href="https://solaci.org/en/2022/09/21/tct-2022-france-tavi-registry-small-annuli/" title="Read more" >...</a>

Resultados alentadores en la válvula mitral percutánea en los pacientes complejos

Is the Cause of Mitral Regurgitation Relevant for MitraClip?

Mitral regurgitation (MR) is the most common valvulopathy: it is present in (at least) 7.5% of patients >75 years old. This pathology can be classified as primary or degenerative MR (DMR) and secondary or functional MR (FMR).   FMR can be caused by dilatation of the left atrium (most often due to atrial fibrillation), occurring in<a href="https://solaci.org/en/2022/09/16/is-the-cause-of-mitral-regurgitation-relevant-for-mitraclip/" title="Read more" >...</a>

Opening Ceremony SOLACI-SOCIME 2022

✔️ Opening Ceremony SOLACI-SOCIME 2022 ✔️ SOLACI-SOCIME 2022 Scientific Session 👨‍🏫 Content: 00:09 – Welcoming words – Dr. Guering Eid-Lidt (MEX) 01:41 – Fully understanding our TAVR implantation views and techniques – Dr. Ole de Backer (DNK) 21:51 – Transcatheter interventional heart failure therapies – Dr. Juan Granada (USA) 43:17 – The revolution in the<a href="https://solaci.org/en/2022/09/15/opening-ceremony-solaci-socime-2022-2/" title="Read more" >...</a>

Structural: Selected Topics in TAVI | SOLACI-SOCIME 2022

✔️ MITRAL VALVE Session ✔️ SOLACI-SOCIME 2022 Scientific Session 👨‍🏫 Content: 00:09 – Welcoming Words – Dr. Jorge Cortés (MEX) 01:16 – TAVR for aortic regurgitation – Dr. Raj Makkar (USA) 18:53 – Reduced leaflet motion: the real clinical impact – Dr. Ole de Backer (DNK) 34:17 – TAVR in bicuspid aortic valve: Clinical evidence<a href="https://solaci.org/en/2022/09/15/structural-selected-topics-in-tavi-solaci-socime-2022-2/" title="Read more" >...</a>

SOLACI-SOCIME 2022 - TAVI Complex Anatomy

TAVI Complex Anatomy – SOLACI-SOCIME 2022

✔️ TAVI Complex Anatomy ✔️ SOLACI-SOCIME 2022 Scientific Session 👨‍🏫 Contents: 00:11 – Welcoming words – Dr. Jorge Cortés (MEX) 01:05 – TAVR in complex anatomy. Which is the limit? – Dr. John Paul Vavalle (USA) 13:27 – TAVR in bicuspid aortic valve – Dr. John Paul Vavalle (USA) 31:27 – Calcified annulus. TAVR or<a href="https://solaci.org/en/2022/09/15/tavi-complex-anatomy-solaci-socime-2022-2/" title="Read more" >...</a>

Jornadas Paraguay: Concurso de Jóvenes Cardiólogos

Watch the Highlighted Presentations of the Paraguay Sessions 2022

The 44th SOLACI Regional Sessions – 15th South Cone Region took place in a hybrid setting (F2F and online) in Asuncion, Paraguay, between June 30 and July 1, 2022. It was a successful event that featured prestigious national and international guests and a world class scientific program.  Next, we share some of the presentations held<a href="https://solaci.org/en/2022/09/14/watch-the-highlighted-presentations-of-the-paraguay-sessions-2022/" title="Read more" >...</a>

La clave para tratar strokes: saber cuando detenerse

Should We Treat Stroke Percutaneously in TAVR?

Since its inception, transcatheter aortic valve replacement (TAVR) has improved greatly. However, there still are five big challenges to be solved: paravalvular leak, conduction disturbances, debilitating stroke, impaired kidney function, and major vascular complications and bleeding. Most cases of stroke are periprocedural and ischemic. So far, they have not been well analyzed in terms of<a href="https://solaci.org/en/2022/09/14/should-we-treat-stroke-percutaneously-in-tavr/" title="Read more" >...</a>

Es viable el alta al otro día en pacientes que reciben TAVI

Can We Discharge TAVR Patients the Same Day?

For over a decade, TAVR has been showing great benefits, but conduction abnormalities such as RBBB and prior A-V block, continue to be one of the biggest challenges, since in different series the need for definite pacemaker implantation (PPM) varies between 17 to 30% in the large, randomized studies of self-expanding valves.   Even though we<a href="https://solaci.org/en/2022/09/14/can-we-discharge-tavr-patients-the-same-day/" title="Read more" >...</a>

¿Son las válvulas autoexpandibles una opción válida en las bicúspides?

TAVR in Bicuspid Patients: Are Outcomes the Same in Men and Women?

Bicuspid aortic valve stenosis (BAV) has not yet been analyzed in large, randomized studies, and TAVR in this scenario has been assessed only by small fairly studies. However, the information available is quite promising.   TAVR in women generally presents more complications than in men, but severe bicuspid aortic valve stenosis receiving TAVR has not been<a href="https://solaci.org/en/2022/08/26/tavr-in-bicuspid-patients-are-outcomes-the-same-in-men-and-women/" title="Read more" >...</a>